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Introduction
Granzyme B (GzmB) is an aspartic acid–directed protease 
that is contained within the specialized secretory granules of 
cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells 
  (Masson et al., 1986; Masson and Tschopp, 1987; Trapani et al., 
1999). Entry of GzmB, as well as other granzymes, into virally 
infected or transformed cells is facilitated by perforin, which is 
a pore-forming protein that is also contained within CTL/NK 
granules (Masson and Tschopp, 1985; Trapani and Smyth, 
2002; Lieberman, 2003). Upon entry into target cells, GzmB 
can initiate apoptosis in the target through restricted proteolysis 
of substrate proteins (Darmon et al., 1995; Martin et al., 1996; 
Andrade et al., 1998; Barry et al., 2000; Browne et al., 2000; 
Sutton et al., 2000).
To date, several substrates for GzmB have been identifi  ed 
and, among these, the BH3-only protein BID has been impli-
cated as playing a particularly important role (Heibein et al., 
2000; Sutton et al., 2000; Alimonti et al., 2001; Pinkoski et al., 
2001; Waterhouse et al., 2005). BID has been proposed to be the 
preferred substrate for GzmB (Pinkoski et al., 2001; Waterhouse 
et al., 2005), and BID proteolysis is thought to initiate apop-
tosis through activating Bax and/or Bak and promoting their 
oligomerization within the mitochondrial outer membrane. 
Oligomerization of Bax/Bak results in permeabilization of mito-
chondria and facilitates escape of intermembrane space proteins 
such as cytochrome c (Kuwana et al., 2002). Release of cyto-
chrome c into the cytosol is especially relevant, as this protein 
acts to initiate the assembly of a complex between Apaf-1 and 
caspase-9, which results in the activation of the latter and pre-
cipitates a series of further caspase activation events culminat-
ing in the death of the cell (Li et al., 1997; Slee et al., 1999; Hill 
et al., 2004).
However, because GzmB can also directly process and acti-
vate caspases, such as caspase-3 and -8 (Darmon et al., 1995; 
Martin et al., 1996; Muzio et al., 1996; Medema et al., 1997; 
Adrain et al., 2005), this provides a more direct route to caspase-
dependent cell death. Several other substrates for GzmB have 
been reported. Among these, ICAD (DFF45) is also thought 
to play an important role in cytotoxic lymphocyte killing, as 
this protein acts as an inhibitor of a DNase (CAD/DFF40) 
that becomes activated during many forms of apoptosis (Liu 
et al., 1997; Enari et al., 1998). Thus, it has been suggested 
that GzmB-mediated proteolysis of ICAD during CTL/NK-
  mediated killing can lead directly to CAD activation and DNA 
degradation (Thomas et al., 2000; Sharif-Askari et al., 2001).
Several studies have debated the relative importance of 
BID versus caspases and other GzmB substrates during CTL/
NK-mediated killing (Sutton et al., 2000; Pinkoski et al., 2001; 
Alimonti et al., 2001; Metkar et al., 2003; Froelich et al., 2004; 
Waterhouse et al., 2005). One model proposes that BID pro-
teo lysis is the critical event in CTL/NK-mediated killing be-
cause BID (of human origin) appears to be more susceptible to 
GzmB-dependent proteolysis than caspases such as caspase-3 
(Pinkoski et al., 2001). However, other studies have reported that 
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BID proteolysis occurs secondary to caspase-3 activation in cer-
tain models (Metkar et al., 2003). One possible reason for these 
discrepant fi  ndings is that groups working in this area use GzmB 
preparations from either murine or human sources. Thus, some 
conclusions have been based on experiments where human 
GzmB has been used in conjunction with mouse cell lines or 
vice versa. This approach is predicated upon the assumption 
that human and murine GzmB have essentially identical sub-
strate preferences, but this has not been established. However, 
this assumption does not take into account the divergence 
  between human and mouse GzmB at residues that may affect 
substrate recognition or catalysis. Although the similarity be-
tween human and mouse GzmB is substantial, these are distinct 
proteases and are likely to display subtle, but important, differ-
ences in substrate selection. Similar considerations probably 
apply to many other conserved proteases, such as caspases.
We provide evidence that human and murine GzmB are 
distinct enzymes. Although both of these enzymes can cleave a 
similar cohort of protein substrates, we have found clear differ-
ences in their ability to cleave important substrate proteins 
such as BID, ICAD caspase-8, and several other substrates. 
These observations suggest that experiments that use GzmB 
(and possibly other granzymes) from one species cannot be 
readily   generalized to other species. These observations have 
broad   implications for our current understanding of the role of 
GzmB, as well as other granzymes, in CTL/NK-mediated killing.
Results
Titration of human and mouse GzmB 
using synthetic substrates
GzmB is a highly conserved protease, as the murine and human 
forms of this granzyme exhibit 69% identity (Fig. 1 A). How-
ever, although the amino acids that make up the catalytic triad 
are perfectly conserved between rat, mouse, and human GzmB 
(Fig. 1 A, residues highlighted in red), several of the residues 
that are predicted to infl   uence substrate recognition exhibit 
 signifi  cant divergence (Fig. 1 A, residues highlighted in blue). 
Because of the high degree of homology between human and 
murine GzmB, it is generally assumed that these enzymes 
cleave essentially the same cohort of substrates upon entry into 
target cells. Because of this, many investigators use these en-
zymes in cross-species experiments where mouse GzmB is used 
to kill human target cells or vice versa. However, the divergence 
seen in residues involved in substrate recognition suggests that 
human and mouse GzmB may not behave in an identical man-
ner toward the same protein substrates.
To explore this issue, we generated recombinant human 
and mouse GzmB in Pichia pastoris and active site–titrated 
these enzymes using the synthetic substrate peptide Ac-IETD-
AFC and the viral serpin CrmA (Fig. 1 B). Using this assay, we 
chose concentrations of the human and murine enzymes that 
displayed equivalent rates of IETD-AFC hydrolysis and used 
these concentrations of GzmB for subsequent experiments (Fig. 1, 
C and D). We then compared hGzmB and mGzmB for their 
ability to process and activate effector caspases within cell-free 
extracts prepared from either human (Jurkat) or mouse (J774) 
cell lines. To permit direct comparison, cell-free extract prepa-
rations were adjusted to the same fi  nal protein concentration 
(10 mg/ml). Effector caspase activation was assessed by mea-
suring the hydrolysis of Ac-DEVD-AFC, which is a peptide 
that is cleaved effi  ciently by caspase-3 and -7, but not by GzmB 
(Sarin et al., 1996).
As illustrated in Fig. 1 E, addition of 100 nM of either 
  human or mouse GzmB to cell-free extracts of human origin 
provoked similar rates of DEVD-AFC hydrolysis, suggesting 
that these enzymes activated effector caspases within the extracts 
with equal effi  ciency. Note that neither granzyme hydrolyzed 
DEVD-AFC when cell-free extract was omitted from the assay 
(Fig. 1 E, left). Essentially identical results were observed when 
cell-free extracts generated from mouse J774 cells were used in 
the same assay (Fig. 1 E, right). These data suggest that human 
and mouse GzmB activate effector caspases (whether of human 
or murine origin) with a similar effi  ciency.
BID is a poor substrate for mouse GzmB
As outlined earlier, it has been suggested that BID is the pre-
ferred substrate for GzmB (Sutton et al., 2000; Pinkoski et al., 
2001; Waterhouse et al., 2005). Proteolysis of BID by GzmB 
results in the exposure of a myristoylation signal sequence that, 
upon myristoylation at this site, promotes translocation of BID 
to mitochondria to induce oligomerization of Bax and Bak on 
the mitochondrial outer membrane (Zha et al., 2000). Because 
cleaved BID is a potent trigger for mitochondrial cytochrome c 
release, proteolysis of this BH3-only protein may well be suffi  -
cient to ensure death of a target cell upon CTL attack. Thus, we 
were interested in determining whether the human and mouse 
forms of GzmB cleaved BID with similar effi  ciency. We also 
compared hGzmB and mGzmB in terms of their ability to pro-
teolytically process caspase-3, -7, and -8, all of which are well 
established as substrates for hGzmB (Adrain et al., 2005). As a 
source of human BID and other human substrate proteins, we 
used cell-free extracts derived from Jurkat cells (Martin et al., 
1996; Slee et al., 1999). As a source of murine substrates, simi-
lar cell-free extracts were generated from the mouse macro-
phage line, J774. To exclude complex outcomes resulting from 
activation of caspases within the extracts caused by the addition 
of exogenous GzmB, we also included 10 μM zVADfmk in 
all reactions to suppress endogenous caspase activity. Note 
that this polycaspase inhibitor does not inhibit GzmB activity 
(Adrain et al., 2005; Adrain et al., 2006).
As Fig. 2 (A and B) illustrates, addition of 100 nM hGzmB 
to the cell-free extracts led to effi  cient proteolysis of BID of 
  human and mouse origin, and to slightly less effi  cient proteo-
lysis of caspase-3 and -7 in the same extracts. In contrast, although 
hGzmB was found to proteolytically process human caspase-8 
(Fig. 2 A), it failed to cleave the mouse counterpart of this 
  caspase (Fig. 2 B). mCaspase-8 was processed upon addition of 
cytochrome c and dATP to J774 extracts to activate the apopto-
some pathway to caspase activation (Fig. S1, http://www.jcb.org/
cgi/content/full/jcb.200612025/DC1), confi  rming that the anti-
body used to detect mcaspase-8 was, indeed, capable of detecting 
the processed form of this enzyme. Thus, mcaspase-8 does not 
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Rather surprisingly, mGzmB failed to cleave BID of  either 
species under conditions where hGzmB clearly did so (Fig. 2, 
A and B). Importantly, mGzmB cleaved both human and 
mouse caspase-3 and -7 very effi  ciently under the same condi-
tions (Fig. 2, A and B), thereby precluding the possibility that 
mGzmB was not active in these experiments. In addition to 
the differences observed in respect to BID proteolysis, it can 
also be seen that mGzmB failed to cleave caspase-8 from either 
species (Fig. 2).
We also performed titrations of human and mouse GzmB 
in Jurkat and J774 cell-free extracts and, again, observed marked 
differences in the ability of these enzymes to cleave BID and 
caspase-8 (Fig. 2, C and D). We also assessed proteolysis of 
  nucleophosmin/B23 in these assays, as this protein has recently 
been reported to be a substrate for hGzmB (Ulanet et al., 2003). 
However, whereas hGzmB effi  ciently cleaved nucleophosmin 
of human origin, mGzmB cleaved this protein very ineffi  ciently 
under the same conditions (Fig. 2 C). Moreover, neither human 
nor mouse GzmB cleaved nucleophosmin within J774 cell-
free extracts (Fig. 2 D). Thus, although human and mouse 
GzmB can proteolytically process caspase-3 and -7 (whether 
of  mouse or human origin), these granzymes exhibited distinct 
differences in respect to their ability to cleave BID, caspase-8, 
and nucleophosmin.
To exclude the possibility that the results we observed 
could be indirect effects, e.g., caused by activation of caspases 
Figure 1.  Comparison of human and mouse GzmB. 
(A) Alignment of human, mouse, and rat GzmB. Residues 
are numbered relative to chymotrypsin. Residues boxed in 
red form the catalytic triad; those boxed in blue highlight 
residues predicted to be involved in substrate binding and 
in determining the extended substrate speciﬁ  city of GzmB. 
(B) Recombinant human GzmB (100 nM total protein) or 
mouse GzmB (200 nM total protein) were incubated for 
10 min at 37°C with the indicated concentrations of DTT-
activated CrmA. Residual GzmB activity was then deter-
mined by ﬂ  uorimetric assay using Ac-IETD-AFC (500 μM) 
as substrate. (C and D) Ac-IETD-AFC hydrolysis by 150, 
100, and 75 nM of P. pastoris–derived human and mouse 
GzmB. GzmB concentrations refer to active enzyme amounts, 
based on active site titrations as described in B. Results 
are representative of three independent experiments. 
(E) (left) Ac-DEVD-AFC hydrolysis in Jurkat cell-free extracts 
(CFE) treated with either human or murine GzmB (100 nM) 
for 30 min. Note that incubation of either granzyme with 
Ac-DEVD-AFC in the absence of cell-free extract did not 
result in peptide hydrolysis. (right) Ac-DEVD-AFC hydroly-
sis in J774 (murine) cell-free extracts treated with either 
human or murine GzmB (100 nM) for 30 min. Results are 
representative of three indepen  dent experiments.JCB • VOLUME 176 • NUMBER 4 • 2007  438
within the cell-free extracts, we repeated these experiments 
 using  purifi  ed recombinant human and mouse BID. As Fig. 3 
  illustrates, both human and mouse BID were cleaved effi  ciently 
by hGzmB. As a control, we also compared the effi  ciency of 
proteolysis of recombinant pro–caspase-7, and this was cleaved 
by hGzmB with comparable effi  ciency to that of BID (Fig. 3). 
However, in complete agreement with the results generated 
  using cell-free extracts, although mGzmB cleaved caspase-7 
with an essentially identical effi  ciency to hGzmB, it failed to 
exert any detectable proteolytic activity toward BID from either 
species (Fig. 3). These data provide robust evidence that human 
and mouse GzmB display divergent activity toward BID, but 
similar activity toward caspase-7.
Differential proteolysis of ICAD by human 
and mouse GzmB
We then extended our analysis to several other proteins that 
have been reported to be substrates for GzmB. ICAD, the 
  inhibitory subunit for the CAD deoxyribonuclease that plays 
a role in apoptosis-associated DNA hydrolysis, has also been 
reported to be a direct substrate for GzmB (Thomas et al., 
2000; Sharif-Askari et al., 2001). Consistent with this, hGzmB 
cleaved ICAD effi  ciently in Jurkat cell-free extracts (Fig. 4 A). 
However, mGzmB failed to cleave human ICAD over a similar 
concentration range, which again underscores the differences 
between the human and mouse granzymes in terms of their 
  substrate preferences (Fig. 4 A). We conducted the same experi-
ment in J774 (mouse) cell-free extracts and, similar to our 
earlier observations made with mcaspase-8 (Fig. 2 B), neither 
GzmB species cleaved mouse ICAD under the conditions 
where human ICAD was readily cleaved by hGzmB (Fig. 4 B). 
We also assessed several additional GzmB substrates in these 
assays (cochaperone p23, CD2-associated protein, and α- tubulin), 
and in each case found substantial differences between the 
  activity of human and mouse GzmB toward these substrates 
(Fig. 4, A and B).
Collectively, these observations suggest that human and 
mouse GzmB are quite distinct enzymes in terms of their activity 
toward the same protein substrates. This raises the possibility 
that mGzmB may rely predominantly upon caspase activation 
to kill target cells.
Inhibition of caspases clonogenically 
rescued cells from mGzmB, 
but not from hGzmB
From the preceding experiments, it was apparent that human 
and mouse BID are poor substrates for mGzmB, whereas both 
human and murine caspases -3 and -7 are readily cleaved by this 
granzyme (Figs. 2 and 3). In contrast, human GzmB cleaved BID 
of either species very effi  ciently (Figs. 2 and 3). An important 
Figure 2.  Differential proteolysis of a variety of sub-
strates by human and mouse GzmB. (A) Cell-free extracts 
(CFE) derived from Jurkat (human) cells were treated with 
100 nM of either human or murine GzmB, as indicated. 
Reactions were analyzed by Western blotting for process-
ing of BID, caspase-3, -7, or -8 at the indicated time 
points. Blots were probed for actin as a loading control. 
Note that 10 μM zVADfmk was included in all reactions 
to suppress the enzymatic activity of caspases processed 
by GzmB. (B) J774 (mouse) cell-free extracts were treated 
with 100 nM of either human or mouse GzmB, as indi-
cated. Reactions were then analyzed by Western blotting 
for the indicated proteins. Once again, 10 μM zVADfmk 
was included in all reactions to suppress the activity of 
caspases activated by GzmB. Results are representative 
of three independent experiments. (C) Titration of human 
versus mouse GzmB into Jurkat (human) cell-free extract 
(CFE). Extracts were incubated with GzmB of either spe-
cies for 60 min at 37°C, followed by probing for the indi-
cated proteins. (D) Titration of human versus murine GzmB 
into J774 (murine) cell-free extract. Extracts were incu-
bated with GzmB of either species for 60 min at 37°C, 
followed by probing for the indicated proteins. Results are 
representative of three independent experiments.HUMAN AND MURINE GRANZYME B ARE DISTINCT ENZYMES • CULLEN ET AL. 439
implication of these observations is that murine GzmB may be 
unable to activate the BID pathway to kill target cells and may 
rely predominantly on direct activation of caspases. This sug-
gests that inhibition of caspases may clonogenically rescue 
cells from mouse, but not human, GzmB.
To test this possibility, we loaded human CEM cells with 
either human or mouse GzmB using the pore-forming protein 
streptolysin O (SLO). As shown in Fig. 5, loading of CEM cells 
with human or mouse GzmB led to very rapid death (within 6 h) 
with all of the typical features of apoptosis. Inclusion of the 
caspase inhibitor zVADfmk in these assays transiently   delayed 
apoptosis induced by hGzmB (Fig. 5). However, within 48–72 h, 
cells treated with hGzmB had essentially all died, ir  respective 
of the presence of the caspase-inhibitory peptide (Fig. 5). 
Figure 3.  Human and mouse GzmB cleave caspase-7 with 
similar efﬁ  ciency, but display differential activity toward BID. 
(A) Recombinant human and mouse BID and recombinant 
  human pro–caspase-7 were incubated for 2 h at 37°C with the 
indicated concentrations of human or mouse GzmB. 10 μM 
zVADfmk was added to all reactions containing caspase-7 to 
inhibit caspase autoprocessing. Products were separated by 
SDS-PAGE and visualized by Coomassie staining. Densitometry 
was used to quantitate the percentage of substrate cleaved 
under each condition, and this is presented graphically below 
the gels. (B) Time-course analysis of BID and caspase-7 proteo-
lysis by human and mouse GzmB. Recombinant proteins (as 
indicated) were incubated at 37°C with 100 nM of either 
  human or mouse GzmB, and reactions were sampled at the indi-
cated time points. Products were separated by SDS-PAGE and 
visualized by Coomassie staining, and densitometry was used 
to calculate the percentage of proteolysis of substrates as in A. 
Rates of proteolysis were as follows: 1 μM hGzmB cleaved 
hBID at 4 μM/min, mBID at 4.6 μM/min, and hcaspase-7 at 
5.6 μM/min. 1 μM mGzmB cleaved hBID at 0 μM/min, 
mBID at 0.13 μM/min, and caspase-7 at 6.5 μM/min. 
  Results are representative of two independent experiments.JCB • VOLUME 176 • NUMBER 4 • 2007  440
In contrast, when the same cells were loaded with mGzmB 
at concentrations that achieved  95% cell death within 6 h in 
the absence of zVADfmk (Fig. 5), these cells were substantially 
protected when the caspase inhibitor was included in the assay. 
Moreover, the protection afforded by zVADfmk was long-term, 
as these cells proliferated upon subsequent culture (Fig. 5 D). 
Essentially identical results were also observed using human 
Jurkat cells in the same assay (Fig. 6, A and B), and these 
cells could also establish colonies when plated in soft agar 
(Fig. 6, C and D).
Although caspase inhibition selectively maintained the 
clonogenic potential of two different human cell lines treated 
with mGzmB, it remained possible that this granzyme could kill 
mouse cells in a caspase-independent manner. Thus, we per-
formed the reciprocal experiment using mouse J774 cells, and 
in this case we used a different polycaspase inhibitor, Q-VD-
Oph (Caserta et al., 2003). As Fig. 7 shows, whereas J774 cells 
were readily killed by both GzmB species, inhibition of  caspases 
only restored clonogenic potential in cells that were treated 
with mGzmB. Furthermore, under conditions where mGzmB 
effi  ciently killed J774 cells, no detectable processing of BID 
was observed, whereas caspase-3 processing was readily de-
tected (Fig. 7 C). In contrast, hGzmB cleaved both BID and 
caspase-3 in the same cells (Fig. 7 C).
Using MCF-7 cells defi  cient in caspase-3, we also ex-
plored whether the absence of this caspase was suffi  cient, on its 
own, to confer protection against mGzmB. For comparison, we 
also used MCF-7 cells reconstituted with caspase-3 by stable 
transfection of a CASP-3 expression plasmid (Janicke et al., 
1998). However, although the absence of caspase-3 did delay 
the onset of GzmB-initiated cell death, no long-term protection 
was seen in the absence of this caspase (Fig. S2, available 
at http://www.jcb.org/cgi/content/full/jcb.200612025/DC1). 
This suggests that GzmB-mediated processing of other cas-
pases, such as caspase-7 (Figs. 2 and 3), is probably suffi  cient 
to kill cells in the absence of caspase-3, and that inhibition of 
both proteases is necessary to achieve clonogenic protection 
from mGzmB.
Collectively, the data presented in this study suggests that 
caspases are essential for apoptosis initiated by mouse, but not 
human, GzmB, and underscore the distinct substrate  preferences 
of these closely related proteases. Although BID and ICAD 
were cleaved readily by human GzmB, neither protein was 
effi  ciently cleaved by the murine form of this protease. These 
results suggest that an apparently minor divergence in primary 
amino acid sequence between two closely related enzymes 
can lead to functionally important shifts in substrate selection. 
A broader implication of these observations is that other prote-
ases that have diverged more substantially between mouse and 
man, such as caspases, are also likely to display different sub-
strate preferences that may profoundly affect their mechanism 
of action.
Discussion
We have shown that human and mouse GzmB behave as dis-
tinct proteases and share only partial overlap in their substrate 
range. In particular, whereas hGzmB effi  ciently cleaved the 
BH3-only protein BID, mGzmB failed to do so. Similarly, 
hGzmB   promoted effi  cient proteolysis of the human forms of 
ICAD and caspase-8, whereas mGzmB failed to cleave these 
proteins. Interestingly, neither human nor mouse GzmB cleaved 
murine ICAD or murine caspase-8 under the conditions used 
in this study. Several other examples of divergent substrate 
preferences between human and murine GzmB were found. 
Collectively, these data demonstrate that human and mouse 
GzmB exhibit clear differences in the cohort of proteins that 
these proteases target upon entry into target cells. These obser-
vations are also supported by a study from Kaiserman et al. 
(2006) that was published during revision of our study, as these 
authors also found similar functional divergence between hu-
man and mouse GzmB.
There has been much debate concerning the relative im-
portance of the substrates cleaved by GzmB (Pinkoski et al., 
2001; Metkar et al., 2003; Froelich et al., 2004; Waterhouse 
et al., 2005). Although some have suggested that BID may be 
the most relevant GzmB substrate during CTL attack, others 
Figure 4.  Differential proteolysis of multiple substrates, including ICAD/
DFF45, by human and mouse GzmB. Titration of human versus mouse 
GzmB into Jurkat (A) and J774 (B) cell-free extracts (CFE). Extracts were in-
cubated for 60 min at 37°C, followed by probing for the indicated pro-
teins. Note that DFF45/ICAD was detected as a doublet in Jurkat cells 
because of alternative splicing.HUMAN AND MURINE GRANZYME B ARE DISTINCT ENZYMES • CULLEN ET AL. 441
have suggested that BID proteolysis is indirect and is mediated 
by caspase-3, which is also activated by GzmB (Metkar et al., 
2003). The contention that BID is a preferential substrate for 
GzmB is supported by studies that have shown that Bcl-2 can 
block GzmB-initiated apoptosis, whereas caspase inhibitors 
fail to do so (Pinkoski et al., 2001). The latter observations 
would support an upstream role for BID, independent of cas-
pase activity, in promoting mitochondrial outer membrane per-
meabilization as a result of Bax/Bak activation. In this scenario, 
inhibition of caspase activity would fail to block mitochondrial 
outer membrane permeabilization, and cells would die in a 
  caspase-independent manner. Bcl-2 would be expected to block 
Figure 5.  Caspase inhibition confers protec-
tion from mouse, but not human, GzmB. CEM 
cells were incubated for 45 min either alone, 
with 100 nM hGzmB, or with 120 nM mGzmB, 
all in the presence of 1.25 μg/ml SLO. Cells 
were then cultured for the remainder of the 
  experiment with or without 100 μM zVADfmk 
as indicated. Note that different amounts of 
GzmB were used to achieve approximately 
the same amount of cell death within 6 h. Cell 
cultures were then assessed at the indicated 
time points by phase-contrast microscopy (A), 
and annexin V/PI staining by ﬂ  ow cytometry 
(B and C). (D) Cell proliferation under the same 
conditions was also assessed by direct hemo-
cytometer counting. Results are representative 
of three independent experiments. Error bars 
represent the mean ± the SD.
Figure 6.  Inhibition of caspase activity by 
zVADfmk confers clonogenic protection from 
mouse GzmB in a human cell line. Human Jur-
kat cells were incubated for 45 min either 
alone, with 120 nM hGzmB, or 133 nM 
mGzmB, all in the presence of 1 μg/ml SLO. 
Cells were then cultured for the remainder of 
the experiment with or without 100 μM zVAD-
fmk as indicated. Note that different amounts of 
GzmB were used to achieve approximately the 
same amount of cell death within 3 h. Cell cul-
tures were then assessed at the indicated time 
points by phase-contrast microscopy (A), and 
annexin V/PI staining by ﬂ  ow  cytometry  (B). 
(C and D) Jurkat cells were treated as described 
above and were then plated into soft agar after 
48 h. Colony formation in soft agar was as-
sessed four weeks after plating. Results are rep-
resentative of three independent experiments. 
Error bars represent the mean ± the SD.JCB • VOLUME 176 • NUMBER 4 • 2007  442
death in this context through antagonizing the effects of BID 
on mitochondria.
The observation that BID is a poor substrate for mGzmB 
suggests that this protease does not effi  ciently activate the BID 
pathway to cell death in the mouse. Consistent with this, al-
though inhibition of caspase activity failed to clonogenically 
rescue cells from hGzmB, clonogenic rescue was readily seen 
when mGzmB was used in the same context. This was true 
  irrespective of whether human or mouse target cells were used. 
These observations have important implications for studies 
where murine granzymes were evaluated in human cell lines 
and vice versa. For example, recent studies have used BID-null 
mouse embryonic fi  broblasts in conjunction with hGzmB to 
conclude that BID is an essential target for GzmB in this 
system (Waterhouse et al., 2005). Our observations suggest 
that mGzmB kills in a predominantly caspase-dependent and 
BID-independent manner, whereas the reverse could be true 
for  hGzmB. However, an alternative interpretation is that 
BID is not important for GzmB-mediated cell death in either 
  organism. Thus, conclusions based on mixing human enzymes 
with mouse substrates (or the reverse) should be interpreted 
with caution.
The implications of our fi   ndings also extend to other 
  related proteases, such as caspases, where it is often assumed 
that human and murine orthologues perform essentially identi-
cal functions. However, the sequence identity between human 
and murine caspase orthologues is typically much lower (on 
  average 40%) than seen with GzmB. This makes it even more 
likely that functionally important differences in the substrate 
range of human and mouse caspase orthologues will emerge 
upon examination of this issue. Indeed, there is already one 
clear example of sequence divergence between murine and human 
caspases that has major functional consequences. Whereas murine 
caspase-12 appears to be a functional enzyme (Kalai et al., 2003), 
human caspase-12 has acquired substitutions that render this 
caspase inactive (Fischer et al., 2002). Although this is clearly 
an   extreme example, it is likely that less obvious examples of 
functional divergence between caspase orthologues will emerge, 
as we have seen for GzmB, when this is explored.
In summary, our data demonstrate that human and mu-
rine GzmB behave as distinct enzymes with divergent substrate 
preferences. These observations illustrate how subtle differences 
in enzyme structure can radically affect substrate selection.
Materials and methods
Materials
The following antibodies were used: anti–caspase-3, anti–human caspase-7, 
anti-XIAP, and anti–human BID (BD Biosciences); anti–mouse caspase-7 
(Millipore); anti–mouse BID (R&D Systems); anti–human caspase-8 (Onco-
gene); anti–mouse caspase-8, (Alexis); anti–α-tubulin and anti-actin (ICN, 
UK); anti-p23 (Afﬁ  nity BioReagents); anti-nucleophosmin (Invitrogen); anti–
CD2-associated protein (Santa Cruz Biotechnology, Inc.); anti-DFF45/
ICAD (Calbiochem and Biosource). The peptides zVADfmk and Ac-DEVD-
AFC were purchased from Bachem, IETD-AFC was purchased from Alexis, 
Noble agar was purchased from BD Biosciences, and SLO was purchased 
from Aalto Bio Reagents. Vivaspin 0.5 ml microcentrifuge concentrators 
were purchased from Sartorius. Unless otherwise indicated, all other re-
agents were purchased from Sigma-Aldrich.
Production of human and mouse GzmB in P. pastoris
The cDNA encoding the mature form of mouse GzmB was cloned into the 
expression vector pPIC6α (Invitrogen). P. pastoris X-33 cells were trans-
formed with pPIC6α.mGzmB via electroporation and were put through two 
rounds of selection in 900 μg/ml blasticidin, resulting in X-33 clones stably 
harboring mouse GzmB expression plasmid. P. pastoris yeast clones stably 
harboring a human GzmB expression plasmid were provided by W. Wels 
(Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus, Frankfurt, 
Germany). Yeast clones expressing hGzmB were grown in 1-liter cultures 
for 3 d at 25°C, whereas clones expressing mGzmB were grown in 2-liter 
cultures for 4 d at 25°C. In both cases, GzmB was puriﬁ  ed from culture 
  supernatants using nickel afﬁ  nity chromatography, followed by extensive 
washing in buffer containing 5 mM imidazole. Puriﬁ  ed GzmB was eluted 
with 500 mM imidazole and washed extensively in PBS, pH 7.2, followed 
by concentration in microconcentrator units (Sartorius).
Figure 7.  Inhibition of caspase activity by 
Q-VD-OPh confers clonogenic protection from 
mouse GzmB in a mouse cell line. Murine J774 
cells were incubated for 45 min either alone, 
with 150 nM hGzmB, or 200 nM mGzmB, all 
in the presence of 1.25 μg/ml SLO. Cells 
were then cultured for the remainder of the 
  experiment with or without 50 μM Q-VD-OPh 
as indicated. Note that different amounts of 
GzmB were used to achieve approximately the 
same amount of cell death within 3 h. Cell cul-
tures were then assessed at the indicated time 
points by phase-contrast microscopy (A), and 
annexin V/PI staining by ﬂ   ow cytometry (B). 
(C) J774 cells were treated as described 
above, and at 24 h samples were removed 
for immunoblotting for the indicated proteins. 
(D and E) J774 cells were treated as described 
above and plated into soft agar after 48 h. 
Colony formation in soft agar was assessed 
3 wk after plating. Results are representative 
of three independent experiments. Error bars 
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Expression and puriﬁ  cation of recombinant proteins in bacteria
The pET15b expression plasmid encoding full-length human BID was pro-
vided by X.-M. Yin (University of Pittsburgh School of Medicine, Pittsburgh, 
PA), the pET23dwHis expression plasmid containing full-length mouse 
BID was provided by X. Wang (University of Texas Southwestern Medical 
Center, Dallas, TX), and G.S. Salvesen (The Burnham Institute of Medical 
  Research, Pittsburgh, PA) provided the pET23b expression plasmid containing 
full-length human caspase-7. Expression plasmids were transformed into the 
bacterial E. coli strain BL21 (DE3) and were expressed and afﬁ  nity puriﬁ  ed 
as previously described (Hill et al., 2004), with the exception that caspase-7 
was induced for 40 min to minimize the production of the processed form 
of this protease. Full-length CrmA was cloned into the expression plasmid 
pGEX4TK2 (GE Healthcare) in frame with the GST coding sequence at the 
N terminus. GST-CrmA was expressed in E. coli DH5α and afﬁ  nity puriﬁ  ed 
using glutathione–Sepharose as previously described (Slee et al., 1999).
Active site titration of recombinant granzymes
1 μM GST-CrmA was activated by incubation with 500 μM dithiothreitol for 
10 min at 37°C. Active CrmA was then incubated with human or mouse GzmB 
for 10 min at 37°C. Residual GzmB activity was then determined by diluting 
samples into PBS containing 500 μM Ac-IETD-AFC and measuring hydrolysis 
of the latter peptide by ﬂ  uorimetery, as described in Fluorometric assays.
Kinetic analysis of substrate proteolysis by granzymes
Typically, 3–4 μg of recombinant human or mouse BID was incubated for 
2–3 h at 37°C with varying concentrations of human or mouse GzmB 
in 10 μl reaction volumes. Human recombinant pro–caspase-7 was treated 
in an identical manner, but with 10 μM zVADfmk added to inhibit caspase 
autoprocessing. Reaction products were separated by SDS-PAGE and 
  visualized by Coomassie blue staining. Densitometry was performed using 
ImageJ software (National Institutes of Health; http://rsb.info.nih.gov/ij/) 
and catalytic rates were calculated using these data.
Cell-free reactions
Cell-free cytosolic S-15 extracts were generated from Jurkat and J774 cells, 
as previously described (Martin et al., 1996; Slee et al., 1999). Typically, 
human and murine extracts were normalized to 10 mg/ml total protein 
content, and then diluted twofold in WCEB (20 mM Hepes, pH 7.5, 
10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 100 μM 
PMSF, 10 μg/ml leupeptin, and 2 μg/ml aprotinin). GzmB and zVADfmk 
were added to the reactions at ﬁ  nal concentrations of 6–100 nM and 
10 μM, respectively. Reactions were incubated for 1–2 h at 37°C to facili-
tate GzmB-mediated proteolysis. Cell-free reactions were then assessed by 
immunoblotting or ﬂ  uorimetric assay.
Fluorimetric assays
Reactions containing Jurkat or J774 cell-free extracts (normalized for total 
protein content) were typically assembled in a ﬁ  nal volume of 10 μl. After 
a 30-min incubation at 37°C, 2.5-μl samples were diluted to a ﬁ  nal volume 
of 100 μl in WCEB containing 50 μM Ac-DEVD-AFC. To determine the 
  activity of recombinant GzmB, protein was diluted in 30 μl PBS containing 
500 μM Ac-IETD-AFC. All samples were measured in an automated ﬂ  uori-
meter (Spectraﬂ  uor Plus; TECAN) at wavelengths of 430 (excitation) and 
535 nm (emission).
Clonogenic assays
For clonogenic assays on Jurkat and J774 cells, a 3-ml bottom agar layer 
was poured on 6-cm culture dishes containing RPMI with 20% fetal calf 
  serum, 1% L-Glutamine, 2 mg/ml sodium bicarbonate, 0.001 mg/ml folic 
acid, 10% cell-conditioned medium, and 0.5% Noble agar, and this was 
allowed to set for 30 min. A top layer, containing a 100-μl aliquot of cells, 
was added to 4 ml of the same medium containing 0.33% Noble agar 
(prewarmed to 37°C), and this was poured over the bottom layer and 
  allowed to set. The agar layer was then overlaid with 2.5 ml of the medium 
(without agar) and incubated at 37°C for 3–4 wk. Plates were washed 
brieﬂ  y in PBS, pH 7.2, and stained for 30 min with a solution of 0.05% 
crystal violet in PBS, pH 7.2, containing 20% methanol.
For clonogenic assays using MCF-7 cells, cells were plated on 6-cm 
culture dishes with RPMI, 20% fetal calf serum, 1% L-Glutamine, and 10% 
cell-conditioned medium and incubated at 37°C for 1 wk. Plates were then 
washed brieﬂ  y in PBS, pH 7.2, and stained for 30 min with a solution of 
0.05% crystal violet in PBS, pH 7.2, containing 3% paraformaldehyde.
Gzmb/SLO-killing assays
Typically, SLO and GzmB were added to cells (at concentrations indicated 
in the ﬁ  gure legends) at 10
6 cells/ml. For clonogenic assays, 30,000 cells 
were treated in a ﬁ  nal volume of 30 μl in 96-well U-bottomed plates, fol-
lowed by incubation at 37°C for 45 min. SLO was deactivated by diluting 
cell cultures 1:10 with RPMI containing 10% FCS, and cells were trans-
ferred to 96-well ﬂ  at-bottomed plates for further observation. Cell death 
was subsequently assessed by ﬂ  ow cytometry using annexin V/propidium 
iodide (PI) staining (Martin et al., 1995).
Image acquisition and analysis
The cell images presented in Fig. 5 A, Fig. 6 A, Fig. 7 A, and Fig. S2 A 
were taken on an inverted microscope (IX71; Olympus) using a 40× 
  objective, and images were captured using a Colorview II camera (Soft 
Imaging System) equipped with Analysis image acquisition software. 
All images were acquired at room temperature. Images of crystal violet–
stained colony formation assays presented in Fig. 6 D, Fig. 7 E, and Fig. 
S2 D were captured on a digital camera (CoolPix 5000; Nikon) and 
  imported into Photoshop (Adobe) for uniform brightness and contrast 
  adjustment. Densitometric analysis of the Coomassie blue–stained gels 
presented in Fig. 3 (A and B) was performed using ImageJ software. All 
Western blot images were scanned from x-ray ﬁ  lm using a scanner (Epson 
Perfection) and Photoshop software. All ﬁ  gures were prepared using Page-
Maker 7.0 software (Adobe).
Online supplemental material
Fig. S1 shows the cytochrome c/dATP–induced processing of caspase-8 
in mouse J774 cell-free extracts. Fig. S2 shows that caspase-3 deﬁ  ciency 
is not sufﬁ  cient to afford clonogenic rescue from human or mouse GzmB. 
Online supplemental material is available at http://www.jcb.org/cgi/
content/full/jcb.200612025/DC1.
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